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Background: Recent data have demonstrated similar outcomes in STEMI patients undergoing primary percutaneous coronary intervention (PCI) 
who are treated with small-molecule platelet glycoprotein IIb/IIIa inhibitors (smGPIs¸ including tirofiban and eptifibatide) compared with those 
treated with abciximab. With regard to the most appropriate timing of smGPIs administration, however, controversy remains. We therefore performed 
an updated meta-analysis to exclusively evaluate the relative safety and efficacy of upstream versus deferred administration of smGPIs in STEMI 
patients scheduled for mechanical reperfusion.
Methods: The published literature was scanned by formal searches of electronic databases (PubMed, EMBASE and the Cochrane Central Register 
of Controlled Trials) and conference proceedings up through August 2009. RCTs were eligible for inclusion if they compared upstream versus deferred 
administration of smGPIs in STEMI patients undergoing primary PCI and had their data reported by the trial investigators.
Results: A total of 8 randomized clinical trials comparing upstream versus deferred administration of smGPIs were included in the present meta-
analysis, involving 1421 patients with STEMI. Pre-procedural TIMI grade 2 or 3 flow was present in 43.2% of the upstream group compared with 
31.0% in the deferred group (OR 1.68, 95% CI 1.33 to 2.11; P < 0.001). The mortality rate in the upstream group did not differ from that of the 
deferred group (3.5% vs. 3.4%; OR 1.04, 95% CI 0.58 to 1.84; P = 0.91). And no significant difference was noted between two groups with respect to 
major bleeding complications (3.1% vs. 2.9%, OR 1.06, 95% CI 0.58 to 1.97; P = 0.84).
Conclusions: In STEMI patients scheduled for primary PCI, upstream administration of smGPIs improves initial epicardial patency before 
angioplasty, without an increase in major bleeding risk. The promising effects on clinical outcomes need to be tested in larger studies.
